Change search
ReferencesLink to record
Permanent link

Direct link
PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.
Stockholm University, Faculty of Social Sciences, Department of Psychology.
Show others and affiliations
2008 (English)In: Neurobiology of Aging, ISSN 0197-4580, Vol. 29, no 8, 1204-1217 p.Article in journal (Refereed) Published
Abstract [en]

The effect of galantamine treatment on cortical acetylcholinesterase (AChE) activity and nicotinic receptor binding was investigated by positron emission tomography (PET) in 18 patients with mild Alzheimer's disease (AD) in relation to galantamine concentration and the patients’ cognitive performances. The first 3 months of the study was of a randomized double-blind placebo-controlled design, during which 12 patients received galantamine (16–24 mg/day) and 6 patients the placebo, and this was followed by 9 months’ galantamine treatment in all patients. The patients underwent PET examinations to measure cortical AChE activity (11C-PMP) and 11C-nicotine binding. Neuropsychological tests were performed throughout the study. Inhibition (30–40%) of cortical AChE activity was observed after 3 weeks to 12 months of galantamine treatment. No significant change in mean cortical 11C-nicotine binding was observed during the study. 11C-Nicotine binding, however, positively correlated with plasma galantamine concentration. Both the changes of AChE activity and 11C-nicotine binding correlated positively with the results of a cognitive test of attention. In conclusion, galantamine caused sustained AChE inhibition for up to 12 months. At the individual level, the in vivo cortical AChE inhibition and 11C-nicotine binding were associated with changes in the attention domain of cognition rather than episodic memory.

Place, publisher, year, edition, pages
2008. Vol. 29, no 8, 1204-1217 p.
Keyword [en]
Alzheimer's disease, acetylcholinesterase, 11C-Nicotine binding, positron emission tomography (PET), cerebrospinal fluid, plasma, cognitive function, attention, galantamine
National Category
URN: urn:nbn:se:su:diva-17382DOI: doi:10.1016/j.neurobiolaging.2007.02.020ISI: 000257302900011PubMedID: 17379359OAI: diva2:183903
This research was sponsored by the Medical Research Council (project no. 05817), Stiftelsen for Gamla Tjänarinnor, KI foundations, Stohne's foundation, and Janssen-Cilag (Sweden and USA).Available from: 2009-01-14 Created: 2009-01-14 Last updated: 2011-01-10Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Almkvist, Ove
By organisation
Department of Psychology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 26 hits
ReferencesLink to record
Permanent link

Direct link